IMMH-010

IMMH-010 is an orally available small molecule ester prodrug of YPD-29B, designed as a novel inhibitor of programmed cell death ligand 1 (PD-L1). It is developed to overcome formulation and stability challenges associated with the parent compound YPD-29B by masking its carboxylic acid group. After administration, IMMH-010 is efficiently hydrolyzed in vivo—primarily by carboxylesterase 1 (CES1)—to release the active metabolite YPD-29B. The drug exhibits potent PD-L1 inhibitory activity and has demonstrated significant antitumor efficacy in preclinical models of melanoma and colon carcinoma. IMMH-010 is currently being evaluated in phase I clinical trials for advanced malignant solid tumors and has also been studied for potential use in neurological disorders[2][4][5][6].

Other names

IMMH 010 maleateIMMH010 maleateIMMH-010 maleateYPD-30 maleateYPD30 maleateYPD 30 maleate